Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott they've received approval to launch a phase II clinical trial of its lead drug in patients with COVID-19.
SNG001 is an inhaled formulation of interferon-beta-1a and is currently being developed to treat people with chronic obstructive pulmonary disease (COPD) that also have respiratory viral infections.
Price: 174 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE
Richard Marsden, chief executive of Synairgen plc (LON:SYN), tells Proactive's Andrew Scott data from the ongoing phase II study of their SNG001 drug suggests it's having the desired effect in boosting the antiviral defences of chronic obstructive pulmonary disease (COPD)...
